Protocol Section List

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Protocol Section List
You are on Page 2567 of 2568:
2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568

Protocol Sections: The Identification Through IPD Sharing Statement are Modules For This Protocol Section

NCTID Brief Title Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Oversight Description Conditions View
NCT00000406 Effects of Strength Training on Knee Osteoarthritis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000405 Effects of Jumping on Growing Bones Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000404 Effects of Comprehensive Care for Knee OA Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000403 Doxycycline and OA Progression Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000402 Calcium and Bone Mass in Young Females Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000401 Oral Collagen for Rheumatoid Arthritis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000400 Alendronate andor Parathyroid Hormone for Osteoporosis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000399 Bone Estrogen Strength Training Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000398 Behavioral Treatment of Fibromyalgia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000397 Behavioral Insomnia Therapy for Fibromyalgia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000396 Arthritis Patient Education for Urban African Americans Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000395 Antifolate Effectiveness in Arthritis Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000394 Acupuncture for Carpal Tunnel Syndrome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000393 A Phase I Trial of Peptide T Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome AIDS Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000392 Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000391 A Phase I Trial of Intranasal Peptide T Safety Toxicity and Pharmacokinetics in Human Immunodeficiency Virus-1 HIV-1 Infected Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000390 Antidepressant Treatment of AIDS Related Depression Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000389 Treatment for Anxiety in Children Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000388 Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder MTA Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000387 Self-Management Therapy for Youth With Schizophrenia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000386 Behavior Therapy for Children and Adolescents With Obsessive-Compulsive Disorder OCD Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000385 Long-Term Lithium Treatment for Aggressive Conduct Disorder Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000384 Treatment of Obsessive-Compulsive Disorder OCD in Children Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000383 Treatment of Post-Traumatic Stress Disorder PTSD in Sexually Abused Children Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000382 Preventing Child Abuse in Infants Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000381 Fluoxetine for Anxious Children Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000380 Growth Hormone Releasing Hormone GHRH Treatment for Age-Related Sleep Disturbances Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000379 Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder PTSD Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000378 Antidepressant Treatment of Melancholia in Late Life Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000377 Preventing the Return of Depression in Elderly Patients Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000376 Cognitive and Drug Therapy for Drug-Resistant Depression Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000375 Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000374 Treatment for First-Episode Schizophrenia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000373 Treatment of Obsessive-Compulsive Disorder Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000372 Glycine and D-Cycloserine in Schizophrenia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000371 Trial of D-Cycloserine in Schizophrenia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000370 Treatment of Social Phobia Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000369 Maintenance Therapies in Bipolar Disorders Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000368 Treatment of Panic Disorder Long Term Strategies Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000367 Prevention of Suicide in the Elderly Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000363 Acute Otitis Media Adjuvant Therapy to Improve Outcome Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000362 Randomized Study of Two Interventions for Liquid Aspiration Short-Term and Long-Term Effects Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000361 Autoimmunity in Inner Ear Disease Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000359 Treatments for Benign Paroxysmal Positional Vertigo BPPV Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000358 Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000357 Buprenorphine Maintenance for Opiate Dependence - 6 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000356 Evaluation of L-alpha-acetylmethadol LAAM in Methadone Patients - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000355 Effects of Buprenorphine and Naloxone in Opiate Addicts - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000354 Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000353 Trial of BuprenorphineNaloxone for Opiate Dependence - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000352 Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000351 Cognitive Correlates of Substance Abuse Part 2 - 16 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000350 Effects of Stimulant Dependence on Human Striatal Dopamine System - 15 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000349 Infusion Laboratory Protocol 5 Flupenthixol - 14 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000348 Infusion Laboratory Protocol 4 Dihydrexidine - 13 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000347 Risperidone for Treatment of Cocaine Dependence in Outpatients - 12 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000346 Cognitive Correlates of Substance Abuse - 11 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000345 Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000344 BuprenorphineNaloxone for Treatment of Opiate Dependence - 9 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000343 Brain Changes in Stimulant Dependent Subjects - 8 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000342 Risperidone for the Treatment of Cocaine Dependence - 7 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000341 Evaluation of Liquid vs Tablet Buprenorphine - 6 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000340 Pemoline in the Treatment of Stimulant Dependence - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000339 Infusion Laboratory Protocol 3 Risperidone - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000338 Infusion Laboratory Protocol 2 Lisuride - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000337 Infusion Laboratory Protocol 1 - Selegeline - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000336 Selegiline in Outpatient Treatment for Cocaine Dependence - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000335 Activity Monitoring Assessment of Opiate Withdrawal - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000334 Comparison of Buprenorphine and Methadone - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000333 Evaluation of Benztropine for Cocaine Craving - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000332 High Dose Nimodipine Treatment Adjunct - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000331 BuprenorphineNaloxone Treatment for Opioid Dependence-Experiment II-3 - 6 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000330 BuprenorphineNaloxone Treatment for Opioid Dependence-Experiment II-2 - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000329 BuprenorphineNaloxone Treatment for Opioid Dependence-Experiment II-1 - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000328 BuprenorphineNaloxone Treatment for Opioid Dependence-Experiment III - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000327 BuprenorphineNaloxone Treatment for Opioid Dependence-Experiment I2 - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000326 BuprenorphineNaloxone Treatment for Opioid Dependence-Experiment 1 - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000325 Psychostimulant Abuse - Novel Treatment Approaches - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000324 Tryptophan and Behavior Therapy for Cocaine Abuse - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000323 Therapeutic Potential of Kappa-Opioids Against Cocaine - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000322 Tyrosine for Methamphetamine Dependence - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000321 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000320 Buprenorphine Formulation Comparison Sublingual Tablet vs Solution - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000319 Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000318 Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000317 Early Phase II Trials for Cocaine Medication Development - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000316 Human Dopamine Transported Imaging in Cocaine Abuse 2 - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000315 Human Dopamine Transported Imaging in Cocaine Abuse 1 - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000314 M-CPP and Fenfluramine in Cocaine Addicts - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000313 Predictive Values of Serotonergic Alterations for Outcome - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000312 Alterations in Serotonergic Functions in Cocaine Addicts - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000311 Combining Behavioral Treatment With Agonist Maintenance - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000310 SerotoninDopamine Antagonism of Cocaine Effect 2 - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000309 SerotoninDopamine Antagonism of Cocaine Effect 1 - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000308 Dextroamphetamine-Cocaine Behavioral Intervention - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000307 Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000306 Dextroamphetamine as Adjunct in CocaineOpiate Dependent Patients - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000305 Amphetamine Cocaine Interaction Study - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000304 Dextroamphetamine as an Adjunct in Cocaine Treatment - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000303 Rapid Evaluation of Baclofen for Treatment of Cocaine AbuseDependence - 6 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000302 Study Comparing Liquid and Tablet Buprenorphine Formulations - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000301 Rapid Evaluation of Amantadine for Treatment of Cocaine AbuseDependence - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000300 Feasibility Study of Take-Home LAAM Medication - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000299 Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000298 Buprenorphine Combination Tablet Feasibility - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000297 Effects of Labetalol on Nicotine Administration in Humans - 14 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000296 Role of Metabolites in Nicotine Dependence 4 - 13 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000295 Progesterone Treatment in Female Smokers - 12 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000294 Effects of Carvedilol on Cocaine Use in Humans - 11 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000293 Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000292 Acute Withdrawal From Smoked Cocaine - 9 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000291 Effects of Labetalol on Human Cocaine Use - 8 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000290 Stress Hormones and Human Cocaine Use - 7 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000289 Role of Metabolites in Nicotine Dependence 3 - 6 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000288 Role of Metabolites in Nicotine Dependence 2 - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000287 Relapse Patterns in Female Cocaine Users - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000286 Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000285 Effects of Phenytoin on Cocaine Use in Humans - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000284 Role of Metabolites in Nicotine Dependence 1 - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000282 Pemoline for Cocaine Abuse - 7 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000281 Pharmacotherapy for Schizophrenic Drug Users - 6 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000280 Glutaminergic Agents for Cocaine Abuse - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000279 Novel Medications for Opiate Detoxification - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000278 Disulfiram for Cocaine-Alcohol Abuse - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000277 Mazindol for Cocaine Abuse - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000276 Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000275 Cocaine Abuse and ADHD - 10 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000274 Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000273 A Laboratory Model for Heroin Abuse Medications - 8 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000271 New Approaches to Cocaine Abuse Medications A - 6 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000270 Brain Imaging Cocaine Effects Medication Development - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000269 Pergolide Treatment for Substance Abusers - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000268 Cocaine Abuse and Attention Deficit Disorder - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000267 Risperidone Treatment in Dually-Diagnosed Individuals - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000266 Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000265 Subjective Effects of Nitrous Oxide in Dental Patients - 17 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000264 SubjectivePsychomotor Effects of Combined Alcohol Nitrous Oxide - 16 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000263 Effects of Combined Alcohol and Nitrous Oxide Intake - 15 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000262 Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000261 Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000260 Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000259 Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000258 Role of Instructions in Nitrous Oxide Effects and Choice - 10 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000257 Effects of Alcohol History on Effects of Nitrous Oxide - 9 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000256 Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000255 Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000254 Isoflurane at Subanesthetic Concentrations - 6 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000253 Effects of Nitrous Oxide A Dose-Response Analysis - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000252 Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000251 Effects of Subanesthetic Concentrations of IsofluraneNitrous Oxide - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000250 Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000249 Effects of Subanesthetic Concentrations of Nitrous Oxide - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000248 Dose Response Trial of Pergolide for Cocaine Dependence - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000246 Rapid Benzodiazepine Detoxification Using Flumazenil - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000245 Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000244 Effects of Dynorphin 1-13 on Heroin Addiction - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000243 Effects of BuprenorphineNaloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000242 Carbamazepine Treatment of Cocaine Dependence - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000241 Flupenthixol Decanoate in Methamphetamine Smoking - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000240 Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence - 22 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000239 Buprenorphine Pharmacology Related to Addiction Treatment - 21 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000238 Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000237 Buprenorphine Detoxification - BBDVI - 19 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000236 Buprenorphine Pharmacology Related to Addiction Treatment - 18 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000235 Alternate Day Buprenorphine Administration Phase XII - 17 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000234 Alternate Day Buprenorphine Administration Phase XI - 16 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000233 Alternate Day Buprenorphine Administration Phase X - 15 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000232 Alternate Day Buprenorphine Administration Phase IX - 14 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000231 Buprenorphine Detoxification With Two Types of Treatment BBD IV - 13 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000230 Buprenorphine Detoxification With Two Types of Treatment BBD III - 12 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000229 Buprenorphine Detox With Two Types of Treatment BBD II - 11 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000228 Buprenorphine Detox With Two Types of Treatment BBD I - 10 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000227 Alternate-Day Buprenorphine Administration Phase VIII - 9 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000226 Alternate-Day Buprenorphine Administration Phase VII - 8 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000225 Alternate-Day Buprenorphine Administration Phase VI - 7 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000224 Alternate-Day Buprenorphine Phase V - 6 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000223 Alternate-Day Buprenorphine Administration Phase IV - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000222 Alternate-Day Buprenorphine Administration Phase II - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000221 Alternate-Day Buprenorphine Administration Phase I - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000220 Gradual Vs Rapid Buprenorphine Detoxification - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000219 Buprenorphine Dose Alteration Study - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000218 Pharmacotherapy and Intensive Treatment - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000217 Pharmacotherapy and Intensive Treatment of Drug Abuse - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000216 Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000215 IV Cocaine Abuse A Laboratory Model - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000214 IV Cocaine Abuse A Laboratory Model - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000213 IV Cocaine Abuse A Laboratory Model - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000212 IV Cocaine Abuse A Laboratory Model - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000211 Treatment Efficacy for Drug Abuse and AIDS Prevention - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000210 Treatment Efficacy for Drug Abuse and AIDS Prevention - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000209 Buprenorphine Dosing Interval - 5 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000208 MethadoneBuprenorphine Cross-Over Study - 4 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000207 Multicenter Clinical Trial of Buprenorphine - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000206 Clinical Rescue Protocol - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000205 Buprenorphine Maintenance Protocol - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000204 Buprenorphine Maintenance for Opioid Addicts - 3 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000203 Buprenorphine Maintenance for Opioid Addicts - 2 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000202 Buprenorphine Maintenance for Opioid Addicts - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000201 Pharmacological Modulation of Cocaine Effects - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View
NCT00000200 Cocaine Effects in Humans Physiology and Behavior - 1 Identification Status Sponsor Collaborators Oversight Description Conditions Arms Interventions Outcomes Eligibility Contacts Locations References IPD Sharing Statement View